980522-A
IPOS

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 477/14, 519/00, A61K 31/41 // (C07D 519/00, 487:00, 477:00)

A1

(11) International Publication Number: WO 97/40048

(43) International Publication Date: 30 October 1997 (30.10.97)

(21) International Application Number: PCT/US97/06626

(22) International Filing Date: 21 April 1997 (21.04.97)

(30) Priority Data:

60/016,184	24 April 1996 (24.04.96)	US
9609741.5	10 May 1996 (10.05.96)	GB

(71) Applicant *(for all designated States except US)*: MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: WILKENING, Robert, R. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). RATCLIFFE, Ronald, W. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). BLIZZARD, Timothy, A. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). - Plc see pg 8

(74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).


(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

(57) Abstract

The present invention relates to carbapenem antibacterial agents in which the carbapenem nucleus is substituted at the 2-position with a naphthosultam linked through a CH_2 group. The naphthosultam is further substituted with various substituent groups including at least one cationic group. The compounds are represented by formula (I). Pharmaceutical compositions and methods of use are also included.



(I)